(Translated by https://www.hiragana.jp/)
Benboubker, Lotfi - Resultats de la cerca - Dipòsit Digital de Documents de la UAB
Pàgina inicial > Resultats de la cerca: Benboubker, Lotfi
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.01 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
8 p, 1.0 MB Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma / Moreau, Philippe (University Hospital Hôtel-Dieu) ; Van De Donk, Niels WCJ (Department of Hematology. Amsterdam University Medical Center) ; Nahi, Hareth (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Nooka, Ajay K (Winship Cancer Institute. Emory University) ; Martin, Thomas (University of California San Francisco) ; Rosinol, Laura (Hospital Clínic i Provincial de Barcelona) ; Karlin, Lionel (Centre Hospitalier Lyon Sud) ; Benboubker, Lotfi (Hôpital Bretonneau) ; Mateos, Maria-Victoria (University Hospital de Salamanca) ; Popat, Rakesh (University College London Hospitals) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Sidana, Surbhi (Stanford University of Medicine) ; Delforge, Michele (University of Leuven) ; Pei, Lixia (Janssen Research & Development) ; Trancucci, Danielle (Janssen Research & Development) ; Olyslager, Yunsi (Janssen Research & Development) ; Uhlar, Clarissa (Janssen Research & Development) ; Stephenson, Tara (Janssen Research & Development) ; Rampelbergh, Rian Van (Janssen Research & Development) ; Banerjee, Arnob (Janssen Research & Development) ; Kobos, Rachel (Janssen Research & Development) ; Usmani, Saad Z (Levine Cancer Institute-Atrium Health)
What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. [...]
2023 - 10.2217/fon-2023-0171
Future oncology (London, England), Vol. 19 Núm. 12 (january 2023) , p. 811-818  
Registre complet - Creative Commons
2.
4 p, 756.5 KB Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS / Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu, France) ; Chari, Ajai (Icahn School of Medicine at Mount Sinai, New York, USA) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Haenel, M. (Klinikum Chemnitz, Germany) ; Touzeau, Cyrille (University Hospital Hôtel-Dieu, France) ; Ailawadhi, Sikander (Mayo Clinic Florida, USA) ; Besemer, Britta (Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Germany) ; de la Rubia Comos, Javier (Catholic University of Valencia) ; Encinas, Cristina (Hospital General Universitario Gregorio Marañón) ; Mateos, M. V (Hospital Universitario de Salamanca) ; Salwender, Hans (AK Altona and AK St. Georg, Hamburg, Germany) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Hulin, Cyrille (Hôpital Haut Lévêque. University Hospital, Pessac, France) ; Karlin, Lionel (Centre Hospitalier Lyon Sud. Hospices Civils de Lyon, France) ; Sureda Balari, Anna (Institut d'Investigació Biomèdica de Bellvitge) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Benboubker, Lotfi (Centre Hospitalier Régional Universitaire (CHRU), France) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Tarantolo, Stefano (Nebraska Cancer Specialists, Omaha, USA) ; Terebelo, Howard (Providence Cancer Center, Southfield, USA) ; Yang, Shiyi (Janssen Research & Development. LLC, USA) ; Wang, Jianping (Janssen Research & Development. LLC, USA) ; Nnane, Ivo (Janssen Research & Development. LLC, USA) ; Qi, Ming (Janssen Research & Development. LLC, USA) ; Kosh, Michele (Janssen Research & Development. LLC, USA) ; Delioukina, Maria (Janssen Research & Development. LLC, USA) ; Goldschmidt, Hartmut (GMMG-Study Group at University Hospital Heidelberg, Germany)
2023 - 10.1038/s41408-023-00805-x
Blood Cancer Journal, Vol. 13 Núm. 1 (march 2023)  
Registre complet - Creative Commons
3.
10 p, 667.7 KB Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX / Kaufman, Jonathan L. (Emory Winship Cancer Institute) ; Dimopoulos, Meletios (The National and Kapodistrian University of Athens (Grècia)) ; White, Darrell (Queen Elizabeth II Health Sciences Centre (Canadà)) ; Benboubker, Lotfi (Centre Hospitalier Régional Universitaire. Hôpital Bretonneau (França)) ; Cook, Gordon (St James's Institute of Oncology (Regne Unit)) ; Leiba, Merav (Assuta Ashdod University Hospital (Israel)) ; Joy Ho, P. (Royal Prince Alfred Hospital. Institute of Haematology (Austràlia)) ; Kim, Kihyun (Samsung Medical Center (Corea del Sud)) ; Takezako, Naoki (National Hospital Organization Disaster Medical Center of Japan) ; Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu) ; Sutherland, Heather J. (The University of British Columbia. Leukemia/Bone Marrow Transplant Program) ; Magen, Hila (Tel Aviv University. Department of Hematology Chaim Sheba Medical Center) ; Iida, Shinsuke (Nagoya City University Graduate School of Medical Sciences) ; Kim, Jin Seok (Yonsei University. Severance Hospital (Corea del Sud)) ; Miles Prince, H. (University of Melbourne. Cabrini Hospital (Austràlia)) ; Cochrane, Tara (Gold Coast University Hospital and Griffiths University (Austràlia)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bahlis, Nizar J. (University of Calgary. Arnie Charbonneau Cancer Institute (Canadà)) ; Chari, Ajai (Icahn School of Medicine at Mount Sinai) ; O'Rourke, Lisa (Janssen Research & Development (Estats Units d'Amèrica)) ; Trivedi, Sonali (Janssen Research & Development (Estats Units d'Amèrica)) ; Casneuf, Tineke (Janssen Research & Development (Estats Units d'Amèrica)) ; Krevvata, Maria (Janssen Research & Development (Estats Units d'Amèrica)) ; Ukropec, Jon (Janssen Global Medical Affairs (Estats Units d'Amèrica)) ; Kobos, Rachel (Janssen Research & Development (Estats Units d'Amèrica)) ; Avet-Loiseau, Hervé (Unite de Genomique du Myelome. IUC-Oncopole (França)) ; Usmani, Saad (Levine Cancer Institute/Atrium Health (Estats Units d'Amèrica)) ; San-Miguel, J. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Universitat Autònoma de Barcelona
High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. [...]
2020 - 10.1038/s41408-020-00375-2
Blood Cancer Journal, Vol. 10 Núm. 11 (january 2020) , p. 111  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem